Angiex
Cambridge, US · Founded 2015 · Delaware corporation · 3 known investors
Angiex develops Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) therapies for solid cancers, using a platform that delivers chemotherapeutic payloads to the nucleus of tumor cells and tumor blood vessel endothelial cells. Its lead asset, AGX101, is a TM4SF1-directed ADC in Phase 1 clinical development for advanced solid tumors.
BiotechHealthtechMedical Devices
Founders & leadership
Angiex was founded in 2015 by Paul Jaminet.
PJ
Paul JaminetinFounder
Board
Investors · 3
Reported raises · per SEC filings
Form D private placements$24.9M disclosed across 2 rounds · 2017–2025
▶$22MraisedSep 2025 · 137 investors · BiotechnologyRule 506(c)
▶$22MraisedSep 2025 · 137 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Jonathan AdamsDirector
- Errik AndersonDirector
- Jason CammDirector
- Fabian HansenDirector
- Paul JaminetExecutive Officer, Director
- Amal AminDirector
- Haijing GuoDirector
- Iain DukesDirector
- Tina NeelDirector
- Offering amount
- $28.4M
- Amount sold
- $22M
- Finders' fees
- $2.4M
- Placement agents
- 10220 SW Greenburg Road, Suite 380
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$2.9MraisedJul 2017 · 3 investors · BiotechnologyRule 506(b)
▶$2.9MraisedJul 2017 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul JaminetExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $2.9M
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlapExelixis20 shared keywordsExelixis is a biopharmaceutical company developing cancer therapies through biotherapeutics and small molecule programs, including bispecific antibodies and antibody-drug conjugates. It advances anti-cancer treatments internally and via industry collaborations across multiple modalities in biologics and small molecules.
Agenus13 shared keywords
Bioworld13 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Amgen11 shared keywordsAmgen develops therapies based on biotechnology and scientific research aimed at treating patients and improving or saving lives. It operates in the biopharmaceutical industry, moving discoveries from the laboratory through clinical development to market.
argenx9 shared keywordsargenx is an immunology company that operates an antibody innovation ecosystem where scientists and antibody engineers develop novel targets, disease pathways, and therapeutic antibodies. It builds a proprietary portfolio of first-in-class product candidates, engineered with academic partners, to translate immunology research into medicines for patients.
Companies competing with Angiex for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Angiex do?
- Angiex develops Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) therapies for solid cancers, using a platform that delivers chemotherapeutic payloads to the nucleus of tumor cells and tumor blood vessel endothelial cells. Its lead asset, AGX101, is a TM4SF1-directed ADC in Phase 1 clinical development for advanced solid tumors.
- Who founded Angiex?
- Angiex was founded by Paul Jaminet in 2015.
- Who are Angiex's investors?
- Angiex's investors include Green Meadow Ventures, K5 Global, OrbiMed.
- How much funding has Angiex raised?
- Angiex has disclosed $24.9M raised across 2 rounds.
- Where is Angiex headquartered?
- Angiex is headquartered in Cambridge, US.